Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

848
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
848
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

525
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
525
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

144
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
144

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Sex-Dependent Prevalence of Sagittal Skeletal, Dental Malocclusions in Romanian Orthodontic Patients: An Observational Study.

Journal of clinical medicine·2026
Same author

Traditional and Modern Predictors of Atherosclerotic Cardiovascular Disease in Patients with T2D and MASLD.

Diagnostics (Basel, Switzerland)·2026
Same author

Lipid Signatures Associated with Diabetic Peripheral Neuropathy in Obesity and Type 2 Diabetes-A Systematic Review.

Journal of clinical medicine·2026
Same author

MASLD and Atherosclerosis in Patients with Type 2 Diabetes Mellitus: A Systematic Review.

Medicina (Kaunas, Lithuania)·2026
Same author

Vitamin D and Vitamin B<sub>12</sub> in Psychiatric Disorders: An Exploratory Systematic Review and Meta-Analysis of Nutrient-Specific Status and Supplementation Evidence.

Diseases (Basel, Switzerland)·2026
Same author

Clinical and Inflammatory Determinants of Heart Failure Severity Following Myocardial Infarction: Implications for Post-Infarction Care.

Journal of cardiovascular development and disease·2026

相关实验视频

Updated: Jan 16, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

5.7K

将指导方针转化为实践:对一组罗马尼亚人进行GLP-1RA治疗的前性现实研究.

Mihaela Simona Popoviciu1,2, Delia Reurean-Pintilei3, Teodor Salmen4,5

  • 1Department of Diabetes, Nutrition and Metabolic Diseases-Clinical Section Internal Medicine I, Bihor County Emergency Clinical Hospital, 410169 Oradea, Romania.

Biomedicines
|September 27, 2025
PubMed
概括

类似葡萄糖类-1受体激动剂 (GLP-1RA) 有效地管理2型糖尿病 (T2DM) 和肥胖症. 在罗马尼亚的患者中,可注射的血糖控制和体重减轻在六个月内显著改善.

关键词:
作为GLP-1受体的激动剂.2型糖尿病是什么? 2型糖尿病是什么?杜拉格卢胺是什么意思脱氧化的使用方法血糖控制 血糖控制 血糖控制肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖现实世界的证据.塞马格卢提德 (semaglutide) 是一种可怕的药物.

更多相关视频

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

906
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.6K

相关实验视频

Last Updated: Jan 16, 2026

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber
09:07

Longitudinal In Vivo Imaging and Quantification of Human Pancreatic Islet Grafting and Contributing Host Cells in the Anterior Eye Chamber

Published on: June 11, 2020

5.7K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

906
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.6K

科学领域:

  • 内分泌学 在内分泌学.
  • 代谢疾病 代谢疾病
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 肥胖和2型糖尿病 (T2DM) 在全球范围内正在上升,增加心脏代谢风险.
  • 类似葡萄糖-1受体激动剂 (GLP-1RA) 建议用于超重和心血管风险的T2DM患者.

研究的目的:

  • 评估罗马尼亚GLP-1RA的实际有效性.
  • 评估T2DM患者的血糖控制,体重减轻 (BWR) 和腰围 (WC) 变化.

主要方法:

  • 一项前性观察性研究,涉及311名成年T2DM患者 (HbA1c > 7.2%,BMI ≥ 25 kg/m2).
  • 患者接受了exenatide,口服或注射性semaglutide或dulaglutide6个月.
  • 监测的主要参数:HbA1c,体重,BMI和WC.

主要成果:

  • 所有GLP-1RA显著改善了HbA1c,BMI和WC (p <0.05).所有GLP-1RA显著改善了HbA1c,BMI和WC (p <0.05).所有GLP-1RA显著改善了HbA1c,BMI和WC (p <0.05).所有GLP-1RA显著改善了HbA1c,BMI和WC (p <0.05).
  • 杜拉古化物显示出最大的HbA1c降低 (-6.69 ± 0.91%).
  • 注射性塞马格卢提德实现了最显著的BWR (-4.60 ± 2.74公斤) 和WC减少,特别是在男性中.

结论:

  • 在现实世界T2DM管理中,GLP-1RA提供了实质性的代谢益处.
  • 这些药物应成为超重/肥胖T2DM患者个性化治疗计划的组成部分.